

**HM Public Access**

Author manuscript

Nat Genet. Author manuscript; available in PMC 2018 May 06.

Published in final edited form as:

Nat Genet. 2017 December ; 49(12): 1693–1704. doi:10.1038/ng.3990.

Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers

Collin M. Blakely^{1,2,11}, Thomas B.K. Watkins^{3,11}, Wei Wu^{1,2,11}, Beatrice Gini^{1,2,11}, Jacob J. Chabon⁴, Caroline E. McCoach⁵, Nicholas McGranahan³, Gareth A. Wilson³, Nicolai J. Birkbak³, Victor R. Olivas^{1,2}, Julia Rotow^{1,2}, Ashley Maynard^{1,2}, Victoria Wang^{1,2}, Matthew A. Gubens^{1,2}, Kimberly C. Banks⁶, Richard B. Lanman⁶, Aleah F. Caulin⁷, John St. John⁷, Anibal R. Cordero⁷, Petros Giannikopoulos⁷, Andrew D. Simmons⁸, Philip C. Mack⁹, David R. Gandara⁹, Hatim Husain¹¹, Robert C. Doebele⁵, Jonathan W. Riess⁹, Maximilian Diehn⁴, Charles Swanton³, and Trevor G. Bivona^{1,2,*}

¹Department of Medicine, University of California, San Francisco, San Francisco, CA 94158, USA²Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA³The Francis Crick Institute, London WC2A 3LY, UK. Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London WC1E 6BT, UK⁴Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA⁵Division of Medical Oncology, Department of Medicine, University of Colorado, Denver, Aurora, CO, USA⁶Guardant Health, Inc., Redwood City, CA, USA⁷Driver Inc., San Francisco, CA, USA⁸Clovis Oncology Inc., Boulder, CO, USA⁹University of California Davis Cancer Center, Sacramento, CA, USA

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

*Corresponding authors: Trevor G. Bivona MD PhD lead contact (Trevor.Bivona@ucsf.edu) and Charles Swanton MD PhD (Charles.Swanton@crick.ac.uk).

¹¹These authors contributed equally to this work.

Author Contributions: C.M.B., T.B.K.W., C.S. and T.G.B. designed the study. C.M.B. performed medical record review, analyzed data and prepared tables and figures. T.B.K.W. performed whole-exome sequencing and clonality analysis and prepared tables and figures with assistance from N.M., G.A.W. and N.J.B. W.W. performed analysis of cell-free DNA sequencing data on patient cohorts and prepared tables and figures. B.G. performed cell line experiments and prepared figures with assistance from A.M. J.J.C. and M.D. performed CAPP-Seq analysis. V.O. and J.R. performed IHC analysis. C.E.M., M.A.G., V.W., A.D.S., P.C.M., D.R.G., H.H., R.C.B., J.W.R., performed medical record review and provided clinical data. K.C.B. and R.B.L. compiled and annotated cfDNA data from 1150 EGFR-mutant positive and 1008 EGFR mutant negative NSCLC patients. A.R.C. extracted DNA and prepared exome libraries from patient tumor samples. A.F.C. and J.S.J. performed exome sequencing alignment and quality analysis. P.G. harvested autopsy tissue and performed pathological assessments. C.M.B. and T.G.B. wrote the manuscript with contributions from all authors.

Competing Financial Interests: K.C.B. and R.B.L. are employees of Guardant Health Inc., A.F.C., J.S.J., A.R.C. and P.G. are employees of Driver Inc. A.D.S. is an employee of Clovis Oncology Inc.

URLs.

<http://www.aacr.org/Research/Research/Pages/aacr-project-genie.aspx#.WMeBiRLytaM>

<http://mutationassessor.org/r3/>

¹⁰University of California San Diego, Moores Cancer Center, San Diego, CA, USA

Abstract

A widespread approach to modern cancer therapy is to identify a single oncogenic driver gene and target its mutant protein product (e.g. EGFR inhibitor treatment in *EGFR*-mutant lung cancers). However, genetically-driven resistance to targeted therapy limits patient survival. Through genomic analysis of 1122 *EGFR*-mutant lung cancer cell-free DNA samples and whole exome analysis of seven longitudinally collected tumor samples from an *EGFR*-mutant lung cancer patient, we identify critical co-occurring oncogenic events present in most advanced-stage *EGFR*-mutant lung cancers. We define new pathways limiting EGFR inhibitor response, including *WNT/*β-catenin and cell cycle gene (e.g. *CDK4*, *CDK6*) alterations. Tumor genomic complexity increases with EGFR inhibitor treatment and co-occurring alterations in *CTNNB1*, and *PIK3CA* exhibit non-redundant functions that cooperatively promote tumor metastasis or limit EGFR inhibitor response. This study challenges the prevailing single-gene driver oncogene view and links clinical outcomes to co-occurring genetic alterations in advanced-stage *EGFR*-mutant lung cancer patients.

Introduction

The current paradigm in cancer genetics and therapy is to view and treat oncogene-positive disease (e.g. *EGFR*-mutant non-small cell lung cancer; NSCLC) primarily through the lens of one oncogenic alteration (e.g. oncogenic, mutant *EGFR*, see Supplementary note). This approach does not address the potential risk of co-occurring genetic alterations present in the cancer, treating one “driver” as mutually exclusive from any other. Despite limited and sporadic reports^{1–5}, the prevalence of co-occurring genetic alterations that impact clinical outcomes in advanced-stage lung cancers with a primary oncogenic driver is largely unknown, although recent work suggests a potential role for *TP53* mutations^{6,7}. This lack of data on the prevalence and impact of multiple co-occurring genetic events exists not only for treatment-naïve cancers but also for cancers that have acquired resistance to the initial targeted therapy (e.g. cancers with EGFR p.Thr790Met). An open question in the field is to what extent co-occurring genetic alterations cooperate with a primary driver gene (e.g. mutant *EGFR*) to promote tumor progression and therapy resistance in both the targeted therapy-naïve and acquired resistance settings (see Supplementary note).

This knowledge gap exists because to date large-scale genome sequencing efforts in NSCLC contain mostly early-stage tumors⁸, leading to the current prevailing model of one driver oncogene in each individual cancer. Yet, early-stage patients are not treated with targeted therapy. In this study, we tested the hypothesis that co-occurring genetic alterations commonly exist and cooperate with the primary driver as co-drivers to promote tumor progression and limit targeted therapy response. Here, we link clinical outcomes to genetic co-alterations in the largest cohort of advanced-stage *EGFR*-mutant lung cancers profiled by multiplex sequencing to date.

Results

cfDNA analysis of advanced *EGFR*-mutant lung cancers

To determine the prevalence of co-occurring genetic alterations in advanced-stage *EGFR*-mutant patients, we undertook a large-scale analysis using a clinically-validated cell free (cf)DNA assay (Supplementary Tables 1 and 2, Methods). This cfDNA exome platform is approved for clinical use and measures single-nucleotide variants, small insertions/deletions, gene rearrangements/fusions, and copy number gain (CNG) across 68 clinically-relevant cancer genes (Supplementary Table 2, Methods)^{9,10}. We defined the landscape of somatic genetic alterations present in 1122 *EGFR* mutation-positive and 1008 *EGFR* mutation-negative patients with advanced-stage (Stage III/IV) NSCLC (Supplementary Tables 3–4, and Datasets 1 and 2).

We filtered for mutations that were non-synonymous and validated or predicted to impact gene function (Methods), yielding 1122 *EGFR*-mutation-positive and 944 *EGFR* mutation-negative cases. This dataset of advanced-stage *EGFR*-mutant patients differs from TCGA and other genomic compendia of lung cancer that contain largely early-stage tumors.

Analysis of the 1122 *EGFR*-mutant patient cohort revealed the widespread presence of co-occurring genetic alterations, in addition to the *EGFR* driver mutation (Fig. 1a). The *EGFR*-mutant cases contained a mean of 2.58 ± 1.7 (S.E.M) genetic alterations beyond *EGFR* (out of the 68 genes profiled). When including the *EGFR* mutation, the range of detectable alterations was 1–13. Most patients (92.9%, 1043/1122) harbored at least one additional variant of known or likely functional significance beyond the *EGFR* driver mutation (Supplementary Dataset 1). The majority (89.8%; 3033/3375) of the genetic co-mutations present in the *EGFR* mutation-positive cohort have verified or likely functional impact (by *in silico* modeling, Methods, Supplementary Data Set 1), with only 10.2% (345/3375) of these co-mutations classified as likely passenger events (neutral or unknown functional impact). 16.1% (415/2578) of the mutations present in the *EGFR* mutation-negative cohort were classified as passenger events ($P = 1.3E^{-11}$, two-tailed Fisher's exact test, OR: 0.64, proportions test, Supplementary Dataset 2; comparing the prevalence of mutations classified as passenger events in the *EGFR* mutation-positive cohort versus the *EGFR*-mutation-negative cohort) (Fig. 1a–b, Supplementary Table 3). The data show that canonical *EGFR* driver mutations co-occur with oncogenic driver alterations in several other genes, including *PIK3CA*, *BRAF*, *MET*, *MYC*, *CDK6*, and *CTNNB1*. Comparison of the frequency of genetic co-alterations present in the *EGFR* mutation-positive samples (n=1122) with those present in the stage-matched *EGFR* mutation-negative samples (n=944) revealed significant enrichment for certain genetic events (q -values determined by two-tailed Fisher's exact test Benjamini-Hochberg correction for multiple hypotheses) within the *EGFR*-mutant cancers (Supplementary Table 3). There was enrichment for co-alterations in *CTNNB1* [frequency of alteration in *EGFR* mutation-positive cases, 5.3% (60/1122) vs. *EGFR* mutation-negative cases, 1.8% (17/944), $q = 2.0E^{-04}$], *CDK6* [frequency of alteration in *EGFR* mutation-positive cases 7.0% (79/1122) vs. *EGFR* mutation-negative cases 3.1% (30/944), $q = 8.0E^{-04}$], *AR* [frequency of alteration in *EGFR* mutation-positive cases, 5.1% (57/1122) vs. *EGFR* mutation-negative cases, 2.6% (25/944), $q = 0.02$], and a modest difference in *TP53*

[frequency of alteration in *EGFR* mutation-positive cases, 54.6% (613/1122) vs. *EGFR* mutation-negative cases, 50.3% (475/944), $q = 0.14$] in the *EGFR*-mutant cohort ($n=1122$) compared to the stage-matched *EGFR* mutation-negative samples ($n=944$) (Fig. 1a–d, Supplementary Table 3, Supplementary Datasets 1 and 2). Pathway-level analysis showed selection for co-alterations in *WNT/CTNNB1* [144/1122 vs. 92/944, $q = 0.06$] and hormone signaling genes (59/1122 vs. 29/944, $q = 0.04$) in the *EGFR*-mutant cohort, whereas alterations in receptor tyrosine kinase (RTK) (310/1122 vs. 361/944, $q = 2.0E^{-06}$), MAPK pathway genes (e.g. *KRAS*) (291/1122 vs. 453/944, $q = 2.8E^{-24}$) and gene fusions (e.g. *ALK*) (48/1122 vs. 67/944, $q = 0.02$) were enriched in the *EGFR* mutation-negative cohort (Fig. 1e, Supplementary Table 2). This large-scale dataset uncovers a potential role for *WNT/CTNNB1* and cell cycle gene aberrations in the pathogenesis of advanced-stage *EGFR*-mutant NSCLC.

The *EGFR* p.Thr790Met mutation arises in over 50% of cases of acquired resistance to first-generation *EGFR* TKIs (erlotinib, gefitinib)¹¹, but is rarely detected (~0.5%) before *EGFR* TKI treatment¹². In the cohort of 1122 *EGFR*-mutant NSCLC samples, 440 had a detectable alteration in *EGFR* encoding the p.Thr790Met mutation. Based on the rare detection of *EGFR* p.Thr790Met in *EGFR* TKI-naïve patients (0.5%)¹², it is likely the vast majority of these *EGFR* p.Thr790Met -positive patients were treated previously with a first (or second)-generation *EGFR* TKI. Similar to the presumed mutual exclusivity of oncogenic driver mutations in treatment-naïve NSCLC, *EGFR* TKI treatment resistance is considered largely a consequence of a single gene alteration, such as that encoding the *EGFR* p.Thr790Met mutation, which is thought to be sufficient to drive acquired resistance to first-generation *EGFR* TKIs in an individual patient¹¹. Using our large clinical cohort ($n=440$ *EGFR* p.Thr790Met positive cases), we tested whether specific genetic co-alterations tended to co-occur with *EGFR* p.Thr790Met, which would suggest a functional role for such co-altered genes in driving *EGFR* TKI resistance in cooperation with *EGFR* p.Thr790Met. We found an increase in the mean number of detectable genetic alterations in *EGFR* p.Thr790Met -positive (2.41 ± 1.89 S.E.M.) compared to *EGFR* p.Thr790Met -negative (2.01 ± 1.77 S.E.M) patients ($P = 4.5E^{-04}$, two-tailed Fisher's exact test, Supplementary Table 4). More frequent alterations in cell cycle (*CDK6*, 43/440 vs. 36/682, $q = 0.08$) and *CCNE1* (39/440 vs. 39/682, $q = 0.28$) CNGs), WNT pathway (*CTNNB1* oncogenic mutations, 33/440 vs. 27/682, $q = 0.12$), hormone signaling (androgen receptor, *AR*, somatic mutations 30/440 vs. 27/682, $q = 0.22$), and epigenetic (*MYC* CNG, 47/440 vs. 41/682, $q = 0.08$) genes and in *KRAS* (21/440 vs. 17/682, $q = 0.24$) and *PDGFRA* (21/440 vs. 11/682, $q = 0.06$) (CNG and oncogenic mutations) and *BRCA1* (31/440 vs. 24/682, $q = 0.10$), were present in the *EGFR* p.Thr790Met -positive cases ($n = 440$) compared with the *EGFR* p.Thr790Met -negative cases ($n = 682$) (q -values determined by two-tailed Fisher's exact test Benjamini-Hochberg correction for multiple hypotheses, Fig. 2a–e, Supplementary Fig. 1a–c and Supplementary Table 4). Corresponding differences in cell cycle (106/440 vs. 117/682, $q = 0.07$), DNA repair (48/440 vs. 51/682, $q = 0.16$), epigenetic (62/440 vs. 68/682, $q = 0.16$), WNT (68/440 vs. 76/682, $q = 0.16$), and hormone (30/440 vs. 29/682, $q = 0.18$) pathway level changes were also observed (q -values determined by two-tailed Fisher's exact test Benjamini-Hochberg correction for multiple hypotheses, Fig. 2f). The finding of co-occurring oncogenic mutations in *KRAS* and *EGFR* is consistent with preclinical

data^{13,14}. In a subgroup analysis of EGFR p.Cys797Ser mutation-positive cases (n=15), which can arise upon acquired resistance to osimertinib (the approved third-generation EGFR TKI with activity against EGFR p.Thr790Met¹⁵), there were recurrent activating alterations in MAPK pathway (including *KRAS* CNG and oncogenic mutations) and cell cycle genes (*CDK4*, *CDK6*), and *AR* CNGs (Supplementary Fig. 1c). These data reveal extensive co-occurring alterations in advanced-stage *EGFR*-mutant NSCLCs, even those with EGFR TKI-resistant forms of mutant *EGFR* (i.e. p.Thr790Met, p.Cys797Ser).

cfDNA linked to clinical outcomes in *EGFR*-mutant lung cancers

We next examined the landscape of somatic genetic alterations present in a cohort of advanced-stage *EGFR*-mutant NSCLC patients in which longitudinal cfDNA analysis and clinical context and treatment response data were available (n=137 samples from 97 patients, Fig. 3a, Supplementary Table 5). Somatic mutations were filtered to remove synonymous mutations and mutations of unknown significance (Methods). We analyzed samples obtained from patients who were TKI-naïve (n=21), progressed on first-line TKI treatment (n=53) and progressed on 2nd line therapy (n=26). The number of detectable somatic alterations increased with each line of therapy, irrespective of age, gender, or tobacco exposure (pre-TKI: mean (95% CI) 3.4 (2.2–4.5), PD 1st line: 3.8 (3.2–4.4), PD 2nd line: 5.2 (4.1–6.2), $R^2 = 0.064$, Slope 0.92, $P = 0.01$, $F = 4.2$, $DF = 97$, One-way ANOVA; (Fig. 3b, Supplementary Fig. 2a–c). Enrichment for the EGFR p.Thr790Met encoding mutation occurred at progression on first-line EGFR TKI (31/53 vs. 0/21, $q = 3.6E^{-5}$), as expected based on the rare detection (~0.5%) of *EGFR*^{T790M} before first-generation EGFR TKI treatment¹² and established incidence of *EGFR*^{T790M} (55%–65%) at acquired resistance to first-generation EGFR TKIs¹¹ (q -values determined by two-tailed Fisher's exact test Benjamini-Hochberg correction for multiple hypotheses, Fig. 3a,c, Supplementary Dataset 3). Upon progression on second-line treatment (EGFR TKI or chemotherapy), there were trends towards selection for co-alterations in *CCNE1* (5/26 vs. 3/53, $q = 0.5$), *NF1* (6/26 vs. 3/53, $q = 0.4$), and *PIK3CA* (7/26 vs. 6/53, $q = 0.5$) (q -values determined by two-tailed Fisher's exact test Benjamini-Hochberg correction for multiple hypotheses Fig. 3a, 3c, Supplementary Dataset 3). Alterations in genes involved in TP53 (pre-TKI vs. PD 2nd line; 6/21 vs. 17/26, $q = 0.20$), RTK (PD 1st line vs. PD 2nd line; 10/53 vs. 11/26, $q = 0.17$), MAPK (PD 1st line vs. PD 2nd line; 10/53 vs. 11/26, $q = 0.17$), Cell Cycle (PD 1st line vs. PD 2nd line; 10/53 vs. 9/26, $q = 0.27$), Epigenetic (PD 1st line vs. PD 2nd line; 4/53 vs. 6/26, $q = 0.20$) and PI3K pathways (pre-TKI vs. PD 2nd line; 1/21 vs. 7/26, $q = 0.20$) were more frequently detected in patients with progression on second-line therapy (q -values determined by two-tailed Fisher's exact test Benjamini-Hochberg correction for multiple hypotheses, Fig. 3d, Supplementary Dataset 3).

We investigated detectable differences in cfDNA between EGFR TKI responders vs. non-responders in 73 samples from 64 patients for whom response to subsequent EGFR TKI treatment was known (Supplementary Table 6). The mean number of functional alterations detected in cfDNA was lower in patients who responded (n=37, mean 2.7, 95% CI: 2.3–3.1) to a subsequent EGFR TKI (of any generation) compared to those who did not respond (n=36, mean 5.2, 95% CI: 4.3–6.0) ($P = 0.0002$, $t = 5.4$, $F = 3.6$, $df = 71$, 95% CI of difference in means 1.6–3.4, unpaired, two-tailed t test, Supplementary Fig. 2d, and

Supplementary Dataset 4). Patients harboring gene level *MET* (0/37 responders vs. 5/36 non-responders, $q = 0.23$, 95% CI [0 ~ 1.15] and OR undefined), *NFI* (0/37 responders vs. 6/36 non-responders, $q = 0.23$, 95% CI [0 ~ 0.90] and OR undefined), *CDK4* (0/37 responders vs. 5/36 non-responders, $q = 0.23$, 95% CI [0 ~ 1.15] and OR undefined), *PIK3CA* (1/37 responders vs. 8/36 non-responders, $q = 0.23$, 95% CI [0.0026 ~ 1.005] and OR = 0.124), or *APC* (0/37 responders vs. 5/36 non-responders, ($q = 0.23$, 95% CI [0 ~ 1.15] OR undefined) alterations were least likely to respond to a subsequent EGFR TKI (q -values determined by two-tailed Fisher's exact test Benjamini-Hochberg correction for multiple hypotheses, Supplementary Fig. 3a–b). Patients whose cfDNA harbored *CDK4* or *CDK6* gene alterations (n=7) also exhibited decreased progression-free survival (PFS) (HR: 13.8, 95% CI [5.1 ~ 36.8], $P = 1.4E^{-11}$, Cox proportional hazard regression test, Supplementary Fig. S3c–d) in response to EGFR TKI treatment compared to patients without detectable *CDK4/6* alterations (n=66). Pathway level alterations in cell cycle genes (1/37 responders vs. 12/36 non-responders, $q = 0.006$ (95% CI: 95% CI [0.0018 ~ 0.613] and OR = 0.083)), MAPK (3/37 responders vs. 12/36 non-responders, $q = 0.03$ (95% CI [0.04 ~ 1.02]:and OR = 0.247), PI3K (1/37 responders vs. 9/36 non-responders, $q = 0.03$ (95% CI [0.0024 ~ 0.867]: and OR= 0.11), and WNT (3/37 responders vs. 8/36 non-responders, $q = 0.19$ (95% CI [0.058 ~ 0.695] and OR = 0.369) also correlated with lack of response to EGFR TKI treatment (q -values determined by two-tailed Fisher's exact test Benjamini-Hochberg correction for multiple hypotheses, Supplementary Fig. 3e). Cell cycle (n=12 positive, n=61 negative, HR 2.8, 95% CI [1.4 ~ 5.9], $P = 0.004$, Cox proportional hazard regression test) and MAPK pathway alterations (n=15 positive, n = 58 negative, HR 1.9, 95% CI [1.0 ~ 3.7], $P = 0.04$, Cox proportional hazard regression test) (Supplementary Fig. 3f–h) were biomarkers of decreased PFS during subsequent EGFR TKI treatment. Patients with *CDK4/6* alterations (n=7) exhibited decreased overall survival (OS) compared to patients without (n=66) (HR: 5.4, 95% CI [1.7 ~ 18.0], $P = 0.002$, Cox proportional hazard regression test, Supplementary Fig. 4). These data suggest selection for increased genetic diversity during iterative tumor progression on therapy and identify biomarkers of poor response to EGFR TKI treatment (i.e. cell cycle and MAPK pathway gene alterations). We observed further evidence for this in a cohort of several individual clinical cases of *EGFR*-mutant NSCLC in which intra-patient longitudinal cfDNA profiling was performed (Supplementary Fig. 5).

cfDNA analysis linked to differential osimertinib response

While mechanisms of acquired resistance to the third-generation EGFR TKI osimertinib have been well-described^{14–17}, mechanisms of primary resistance have not been well characterized. We identified 41 patients who underwent cfDNA analysis prior to treatment with osimertinib for whom clinical response, PFS, and OS to subsequent osimertinib treatment were known (Supplementary Table 6 and Supplementary Dataset 4). Alterations in *MET* (3/21), *NFI* (5/21), *CDK4* (3/21), *CCNE* (3/21), *CDK6* (2/21), *PIK3CA* (6/21) and *APC* (5/21) were only found in patients with primary resistance to osimertinib treatment (Fig. 4a–b, Supplementary Dataset 4). Patients with cfDNA alterations in *CDK4* or *CDK6* (n=5) exhibited decreased PFS to osimertinib compared to patients without (n=36) detectable *CDK4/6* alterations (Median PFS 0.7 months (95% CI: 0.7-NR) vs. 11.2 months (95% CI: 6.2-NR), HR: 10.3, 95% CI [3.0 ~ 34.7], $P = 3.7E^{-06}$, Cox proportional hazard

regression test, Fig. 4c–d), although no statistically significant difference in OS was observed (Supplementary Fig. 4c). Pathway level alterations in cell cycle genes (0/20 responders vs. 8/21 non-responders, $q = 0.03$ (95% CI [0 ~ 0.47]: and OR undetermined), MAPK (1/20 responders vs. 7/21 non-responders, $q = 0.15$ (95% CI [0.0025 ~ 1.146] and OR=0.126), PI3K (0/20 responders vs. 7/21 non-responders, $q = 0.04$ (95% CI [0 ~ 0.667]: and OR undetermined), and WNT (2/21 responders vs. 7/21 non-responders, $q = 0.33$ (95% CI [0.023 ~ 1.65] and OR = 0.26) were associated with lack of response to osimertinib treatment (q -values determined by two-tailed Fisher's exact test Benjamini-Hochberg correction for multiple hypotheses, Fig. 4e). Decreased PFS to subsequent osimertinib treatment was also associated with cell cycle gene alterations (n=33 alt. negative, median PFS 11.2, 95% CI: 8.8-NR vs. n=8 alt. positive, median 1.5 months, 95% CI: 0.7-NR, HR 5.4, 95% CI [2.0 ~ 14.5], $P = 0.0002$, Cox proportional hazard regression test, Fig. 4f–g), with a trend towards a difference in OS (OS 17.1 vs. 4.3 months, HR 1.7, 95% CI [0.6 ~ 5.2], $P = 0.4$, Cox proportional hazard regression test, Supplementary Fig. 4d). These data highlight potential roles for MAPK, PI3K, and WNT pathway alterations in driving primary resistance to osimertinib and uncover cell cycle gene aberrations (specifically in *CDK4/6*) as a clinical biomarker of osimertinib non-response (i.e. primary resistance) in advanced-stage EGFR p.Thr790Met -positive NSCLC. Thus, co-occurring genetic alterations may function as co-drivers of tumor progression and drug resistance and create genetic diversity that is advantageous for cancer evolution.

Longitudinal spatial-temporal genomic profiling

We next leveraged the uncommon opportunity to analyze a NSCLC clinical case by both tumor-based whole-exome sequencing (WES) and cfDNA profiling over six years of disease progression: from the initial diagnosis of surgically-resectable disease, through metastatic progression first in mediastinal lymph nodes, then in lungs, bone, and brain over time, during which the patient was treated with erlotinib followed by the third-generation EGFR TKI rociletinib¹⁸ (Supplementary Fig. 6). Seven tumor specimens (4 lung, 2 bone, 1 lymph node), including four obtained at autopsy upon lethal tumor progression on rociletinib, and six plasma specimens were analyzed longitudinally.

The WES analysis showed that over 75% of the coding mutational burden was truncal (i.e. ubiquitous and clonal) at diagnosis but this decreased to 50–58% at the time of full cancer evolution (patient death) via the emergence of subclonal mutations through tumor progression and first- and second-line EGFR TKI treatment and resistance (Fig. 5a). The genetic-co-alterations present in this patient by longitudinal tumor-based exome sequencing are consistent with our cfDNA analysis of the broader cohort of advanced-stage *EGFR*-mutant NSCLC (Fig. 1–4), with evidence of cell cycle, WNT, and PI3K pathway alterations. Multiple functionally-relevant somatic co-alterations were present in early-stage disease (R1), including clonal and truncal *EGFR* variant p.Glu746_Thr751delinsLeu (c. 2233_2252delinsAATT:chr7:g.55242463_55242482delinsAATT (hg19); NM_005228), *CTNNB1* variant p.Ser37Phe (c.110C>T, chr3:g.41266113C>T (hg19);NM_001904)¹⁹, *SMAD4* variant p.Leu146*, (c.437T>G, chr18:g.48575677T>G (hg19);NM_005359) and *RBM10* variant p.Ser10* (c.269C>A, chrX:g.47032594C>A (hg19);NM_005676) as well as *CDK2NA* copy number loss (Fig. 5a–b, Supplementary Fig. 7 and Supplementary Datasets

5 and 6). Acquisition of *PRKCA* variant p.Asn468Ile (c.1403_1404AC>TA, chr17:g.64738757-64738758AC>TA (hg19);NM_002737)²⁰ and *PIK3CA* variant p.Gly106Val (c.317G>T, chr3:g.178916930G>T (hg19);NM_006218)²¹, and CNG in the genomic region encoding *EGFR*, *CDK6*, *MET*, and *BRAF* all occurred upon mediastinal lymph node metastasis (R2) (Fig. 5a–c, Supplementary Fig. 7 and Supplementary Datasets 5 and 6). Progression on initial EGFR TKI (erlotinib) occurred with acquisition of the *EGFR* variant Thr790Met (c.2369C>T, chr7:g.55249071C>T (hg19);NM_005228), found in ~60% of *EGFR*-mutant NSCLC patients who progress on first-generation EGFR TKI¹¹, and the persistence of additional co-alterations including *CTNNB1* variant p.Ser37Phe and *PIK3CA* variant p.Gly106Val. Our data suggest the *PIK3CA* variant p.Gly106Val arose before both EGFR TKI treatment and *EGFR* variant p.Thr790Met (Fig. 5a and Supplementary Fig. 8). The data suggest that the *EGFR* variant p.Thr790Met arose twice in this case in a previously unreported instance of independent dual clones, as it was found in metastatic sites that harbored *PIK3CA* variant p.Gly106Val (R3-left lung at erlotinib progression, R4-left lung at rociletinib progression, R6-right lung at rociletinib progression) and those that did not (R5-right rib metastasis, R7-spine metastasis), although despite relatively deep sequencing coverage (250–600 fold across the tumor samples) we cannot completely rule-out that a rare subclonal common progenitor cell harboring *EGFR* variant Thr790Met existed in the primary tumor (Fig. 5a–c, Supplementary Fig. 8). Additional subclonal genetic co-alterations, including *PIK3CA* variant p.His1047Arg (c.3140A>G, chr3:g.178952085A>G (hg19);NM_006218) (R5-right rib), *RBI* variant p.Arg857His (c.2570G>A, chr13:g.49050886G>A (hg19);NM_000321) (R4-left lung), *CHD4* variant p.His1151Pro (c.3452A>C, chr12:g.6697477T>G (hg19);NM_001273) (R6-right lung) and *TLR4* variant p.Arg289Gln (c.866G>A, chr9 g.120475272G>A (hg19);NM_138554) (R5-right rib) arose with tumor progression on rociletinib (Fig. 5a–c). The activating *PIK3CA* variant p.Gly106Val²¹ was not found in all of the post-rociletinib metastatic sites (present in R4, R6; absent in R5, R7), demonstrating lesion-specific heterogeneity (Fig. 5a–b). A subclonal *PIK3CA* oncogenic variant p.His1047Arg²² was found in R5 (right rib, post-rociletinib), suggesting another instance of parallel evolution in this cancer: two different *PIK3CA* oncogenes (Fig. 5a–c, Supplementary Fig. 8). Although an *RBI* variant p.Arg857His was detected in R4 (left lung- at rociletinib progression) and *RBI* inactivation is associated with transition from lung adenocarcinoma to small cell carcinoma upon acquired EGFR TKI resistance^{23,24}, there was no evidence of transition to small cell histology in this case perhaps due to absence of a somatic *TP53* alteration (Supplementary Fig. 6).

While plasma samples for cfDNA analysis were unavailable for the initial clinical events (i.e. before erlotinib treatment), coupling serially-acquired cfDNA data (Methods) with tumor biopsy-based WES revealed examples of ubiquitous (e.g. *EGFR* variant p.exon19del, *CTNNB1* variant p.Ser37Phe) and lesion-restricted (*PIK3CA* variant p.Gly106Val, *RBI* variant p.Arg857His, *TLR4* variant p.Arg289Gln) mutations in the plasma (Fig. 5d). Thus, cfDNA analysis integrates multiple metastatic tumor lesions.

Functional significance of co-occurring genomic alteration

Similar to our larger cohort of *EGFR*-mutant NSCLC patients (Fig. 1–4), this case highlights the co-occurrence of genetic alterations within the WNT (*CTNNB1* variant p.Ser37Phe),

PI3K (*PIK3CA* variant p.Gly106Val), and cell cycle pathways (*CDK6* CNG, and *CDKN2A* loss). We hypothesized such co-occurring alterations might function non-redundantly to drive tumor metastasis or limit targeted therapy response (See Supplementary note and Fig. 6).

Clonal analysis of genetic alterations detected in cfDNA

Our data (Fig. 5) suggest that subclonal co-occurring oncogenic driver events can influence tumor progression and response to EGFR TKI treatment. To assess whether subclonal events are common in advanced-stage *EGFR*-mutant lung cancers more broadly, we assessed whether co-occurring genetic alterations detected in the cfDNA of 1122 advanced-stage *EGFR*-mutant NSCLC patients were clonal or subclonal (see Supplementary note and Supplementary Fig. 10). Our method inferred the founder canonical *EGFR* mutations (encoding p.Leu858Arg and p.Glu746_Ala750del) as mostly clonal in the 1122 patient advanced-stage *EGFR*-mutant NSCLC cohort, as expected (respectively: ~86.5%, 332/384; ~89.7%, 350/390, $P = 0.19$, Fisher's exact test. 95% CI of difference in two population proportion: $-1.3\% \sim 7.7\%$, OR = 0.96). We further found advanced-stage *EGFR* mutation-positive NSCLCs are more likely to harbor subclonal genetic alterations than advanced-stage *EGFR* mutation-negative NSCLCs (Fig. 7a, Supplementary Datasets 1 and 2, 36.6% (1156/3157) subclonal alterations in *EGFR*-mutation positive vs. 24.9% (572/2291) subclonal events in *EGFR*-mutation negative cases, ($P = 2.2E^{-16}$, Fisher's exact test [95% CI of difference in two population proportion: $9.2\% \sim 14.1\%$], OR=1.47). Subclonal alterations were also more commonly found in the *EGFR* variant p.Thr790Met-positive samples (Fig. 7b, Supplementary Dataset 1, 39.7% (604/1519) in *EGFR* variant p.Thr790Met-positive vs. 33.3% (586/1760) in *EGFR* variant p.Thr790Met-negative cases, $P = 0.02$, Fisher's exact test [95% CI of difference in two population proportion: $3.1\% \sim 9.7\%$], OR 1.19). Relative to the clonal founder *EGFR* mutation, *EGFR* variant p.Thr790Met was more frequently subclonal (~71.1% clonal; 313/440, compared to founder *EGFR* mutations p.Leu858Arg and p.Glu746_Ala750del ~ 95% clonal (as above), $P = 2.2E^{-16}$, Fisher's exact test, OR=1.83), a finding of clinical relevance given that subclonal *EGFR* variant p.Thr790Met may be linked to inferior clinical response to third-generation EGFR TKI treatment²⁵. The subclonal frequency of other common variants is also described (see Supplementary note).

Discussion

This study sheds new light on the genetic basis of oncogenesis and cancer progression by revealing that multiple co-occurring oncogenic events are present in the vast majority of advanced-stage *EGFR*-mutant lung cancers. These new data challenge the current view of the genetic basis of *EGFR*-mutant lung cancer as a single-oncogene disease wherein oncogenic, mutant *EGFR* is mutually exclusive from any other oncogene (Fig. 8). Our findings highlight the importance of deploying more informed and genomically-empowered molecular diagnosis, monitoring, and dynamically-applied rational polytherapy strategies to address the clonal and subclonal co-alterations that drive disease progression and drug resistance in order to better control this deadly cancer. Our data are reminiscent of recent findings in myeloproliferative neoplasms²⁶ and prompt re-examination of the presence and

clinical impact of co-occurring genetic alterations in other cancer types using large datasets such as the one here to enable a powered analysis.

We identify new pathways that promote *EGFR*-mutant lung cancer progression and limit *EGFR* TKI response. Examples include *WNT*/ β -catenin and cell cycle gene alterations (Fig. 4–6; see Supplementary note). Overall, the widespread presence, evolution, and clinical impact of co-occurring genetic alterations within advanced-stage *EGFR*-mutant lung cancers uncovered here re-shapes the current view of oncogene-positive lung cancer and offers future directions for both basic and clinical research that hold promise for improving current treatments for this aggressive cancer.

Online Methods

Patients

IRB-approval for the study # 16-19636 was granted by the UCSF IRB on May 13, 2016. Per the UCSF IRB the study does not involve human subjects as defined by the federal regulations summarized in 45 CFR 46.102(f), and hence does not require further IRB oversight, and requirement for informed consent was waived. For *EGFR*-mutation positive and *EGFR*-mutation negative cohorts selection for inclusion were met if patients had a known diagnosis of stage III or Stage IV NSCLC. For *EGFR*-mutation positive, 1122 consecutive samples from 1006 patients from March 2015 to April 2016 in whom a non-synonymous mutation in *EGFR* of known or predicted functional significance (see below) was identified on the Guardant 360 clinical assay were included for analysis. *EGFR* copy number gain by itself was included in the *EGFR*-mutation negative cohort. The *EGFR*-mutant negative cohort consisted of all other advanced staged NSCLC patients from the time period of January 2016-April 2016 (1008 samples from 999 patients). Chart review of *EGFR*-mutant Guardant cases from patients at UCSF, UCSD, UC Davis, and University of Colorado was carried out by the study investigators to identify patient demographic information and to determine when the Guardant 360 assay was sent in relation to the patients' treatment course. Objective response, PFS, and OS to *EGFR* TKI therapy were determined by retrospective chart review for clinical assessment and direct radiographic review by study investigators when possible. Composite clinical evaluation that integrated clinical and radiographic information was used to identify responders from non-responders. (Responder = radiographic and/or clinical improvement by investigator assessment, Non-responders = radiographic SD or PD (by RECIST 1.1 criteria, or clinical decline, or death prior to imaging). The time-to-event outcomes, including progression free survival and overall survival were estimated using Kaplan-Meier method.

Cell-Free DNA Analysis

Samples were shipped to a Clinical Laboratory Improvement Act (CLIA)-certified, College of American Pathologists-accredited laboratory (Guardant Health, Redwood City, California). Cell-free DNA (cfDNA) was extracted from whole blood collected in 10mL Streck tubes. After double centrifugation, 5ng – 30ng of cfDNA was isolated for digital sequencing as previously described^{9,27}. For *EGFR*-mutant positive NSCLCs, samples were run on 68-gene panel or 70-gene panel, but only the 68 genes in common were included in

this analysis (Supplementary Table 2). Sequencing data was analyzed using the Guardant Health clinical analysis bioinformatics pipeline to identify single nucleotide variants (SNVs) in 68 genes (150kb panel footprint), CNGs in 16, indels in *EGFR* and fusions in *ALK*, *RET*, *ROS1*, *NTRK1*, *FGFR2*, and *FGFR3*^{9,27}. All cell-free DNA fragments, both leukocyte- and tumor-derived, were simultaneously sequenced. The variant allele fraction (VAF) was calculated as the proportion of cfDNA harboring the variant in a background of wild-type cell-free DNA. Reporting thresholds for SNVs, indels, and fusions were 1–2 molecules and 0.01%–0.04% allelic fraction with 0.2%–0.3% 95% limits of detection and >99.9999% per-position analytical specificity^{9,27}. To identify CNGs a large training set, probe-level unique molecule coverage was normalized for signal saturation, individual probe efficiency, GC content, and overall unique molecule throughput and robustly summarized to generate a quantitative gene-level unique molecule representation. Relative quantitation was determined by comparison of this representation to the inferred diploid baseline on a per-gene level. Reporting thresholds were based on training set-established decision thresholds for both absolute copy number deviation from per-sample diploid baseline and deviation from the baseline variation of probe-level normalized signal in the context of background variation within each sample's own diploid baseline. Reporting threshold for CNGs was 2.12 copies with a 2.24–2.76 gene-specific 95% limits of detection and 100% analytical specificity. For clonality analysis, first, the mutational allele frequency (MAF) was normalized by copy numbers of the same genes with CNGs and the largest MAF within each was selected as the normalized Max-MAF; second, the ratio of the MAF of each mutational allele over Maximum-percentage detection (Max-pct) within a case was computed, and the probability distribution was plotted using kernel density estimation. To determine the cut-off of percentage of normalized MAF as clonal or subclonal of each mutation, we implemented aforementioned algorithms to the case with both tumor tissue exome sequencing and cfDNA sequencing encoding EGFR p.exon19del, EGFR p.Thr790Met PIK3CA p.Gly106Val, CTNNB1 p.Ser37Phe, RB1 p.Arg857His and TLR4 p.Arg289Gln reported in this study (Fig. 5 and Supplementary Fig. 10). The value of 0.2 was defined as a robust cutoff for subclonal or clonal mutations resulting in 100% sensitivity and 100% specificity, as all somatic variants identified through this method as subclonal or clonal in cfDNA were also correctly identified as subclonal or clonal in patient tumor samples (Supplementary Fig. 10). For longitudinal case (Fig. 5d), cell-free DNA was isolated from 1 ml of frozen plasma and analyzed as described^{5,28}. Clinical data was collected by review of medical records under an IRB-approved protocol (UCSF). Non-synonymous mutations from EGFR-mutant positive and negative datasets were further processed using R statistical computing program (version 3.3). Unknown significant variants were filtered out by using COSMIC (V79), GENIE (see URLs) and prediction algorithm see URLs).

Whole-exome sequencing and analysis

Informed consent was obtained from the patient and patient's family for study of biological materials and clinical records obtained from the patient. DNA was extracted from FFPE for primary tumor and frozen tumor tissue samples and matched non-tumor tissue using the Qiagen Allprep DNA/RNA Mini Kit. The library preparation protocol was based on the Agilent SureSelect Library Prep and Capture System (Agilent Technologies, Santa Clara, CA). Quantitation and quality were assessed using the Qubit Fluorometer (Thermo Fisher).

DNA concentration was determined to be greater than 2.5 ng/ul and the overall quantity > 500ng. By Nanodrop, the 260/280 ratio was greater than 1.7. DNA was resuspended in a low TE buffer and sheared (Duty Cycle 5%; Intensity 175; Cycles/Burst: 200; Time: 300s, Corvaris S2 Ultrasonicator). Bar-coded exome libraries were prepared using the Agilent Sure Select V5 library kit per manufacturer's specifications. The libraries were run on the HiSeq2500.

Alignment

Raw paired end reads (100bp) in FastQ format generated by the Illumina pipeline were aligned to the full hg19 genomic assembly obtained from USCS, gencode 14, using bwa version 0.7.12. Picard tools version 1.117 was used to sort, remove duplicate reads and generate QC statistics. Tumor DNA was sequenced to median depth of 303X (range 114.39–383.41) and the matched germline DNA to average depth of 231.65.

Exome analysis

SNV, INDEL and Dinucleotide substitution calling, identification and classification of driver mutations, somatic copy number aberration calling, subclonal deconstruction and phylogenetic tree construction were performed as described²⁹.

Classification of SCNAs

SCNA events were defined as segments called by ASCAT \geq 400kb in size that met set thresholds. Segments with a combined raw nMinor and nMajor greater than a 1.5 times the ASCAT derived ploidy for their specific tumor region were considered SCNA gains. SCNA losses had an integer nMinor value of 0 and a combined raw nMinor and nMajor of less than 1.25 times ploidy for their specific tumor region.

Incorporation of p.Thr790Met mutation into phylogenetic reconstruction

In order to create an accurate subclonal phylogeny it is necessary to remove mutation clusters that violate two evolutionary principles. Firstly, the pigeonhole principle which ensures that two mutation clusters cannot be considered to be on separate branches of an evolutionary tree and thus be independent if the cancer cell fraction values of the two clusters together exceeds 100% within region of a tumor. Secondly, a descendent clone must have a smaller cancer cell fraction than its ancestor within each and every tumor region, referred to as the 'crossing rule'. Using these principles, it can be determined whether particular mutation clusters conflict with each other and cannot be fitted to the same evolutionary tree.

The subclonal phylogeny illustrating the entire course of the patient's disease was derived following these two principles and the methods of multi-sample subclonal deconstruction and tree construction in²⁹. However, the SNV encoding EGFR p.Thr790Met did not cluster with any other SNVs following these methods due to its unique CCF profile across R3, R4, R5, R6 and R7. No other SNV appears clonal in all these regions as well as being absent from both R1 and R2. As cluster 7 and the EGFR p.Thr790Met encoding mutation appear clonal in R3, R4, and R6 but cluster 7 is absent from R5 and R7 and the EGFR p.Thr790Met encoding mutation is present they cannot, by the crossing rule, be present in the same

population of cells. In addition, as cluster 7 was present clonally in R2 before Erlotinib treatment while the EGFR p.Thr790Met encoding mutation is absent from R2, it follows that cluster 7 is likely to have arisen before the EGFR p.Thr790Met encoding SNV.

The most parsimonious solution to this violation of the crossing rule, assuming that the cancer cell fractions are correct, is that there are two independent origins of the EGFR p.Thr790Met encoding SNV. p.Thr790Met encoding SNV (A) would occur in a cell already containing the SNVs from cluster 7, and go on to become clonal post-Erlotinib treatment in R3, R4 and R6. p.Thr790Met encoding SNV (B) would occur in a population of cells lacking the SNVs present in cluster 7 and go on to become clonal in R5 and R7 post-Erlotinib. These possible origins of the EGFR p.Thr790Met encoding SNV are indicated on the subclonal phylogeny that can be seen in Supplementary Figure 8 by the placement of a magenta square on the relevant branches.

Cell Lines and Reagents—The HCC827 (EGFR p.Glu746_Ala750del) and HEK293-FT cell lines were obtained, authenticated, and cultured as recommended by the American Type Culture Collection (ATCC). These cell lines confirmed to be negative for mycoplasma. HCC827 cells were cultured in RPMI 1640 media (Hyclone, GE Healthcare) supplemented with 10% FBS (SAFC, Sigma-Aldrich), 1X penicillin and streptomycin (UCSF, Cell Culture Facility). HEK293-FT cells were cultured in DMEM media (Hyclone, GE Healthcare), supplemented with 10% FBS, 0.1X penicillin and streptomycin. All cell lines were grown at 37 °C, in a humidified atmosphere with 5% CO₂. Erlotinib and rociletinib were purchased from Selleckchem.

Mammalian expression vectors pQCXIB empty (w335-1) was a gift from Eric Campeau (Addgene plasmid # 17487)³⁰; pBABE-puro was a gift from Hartmut Land & Jay Morgenstern & Bob Weinberg (Addgene plasmid # 1764)³¹; pCMV-VSV-G (Addgene plasmid # 8454) and pUMVC (Addgene plasmid # 8449)³² were a gift from Bob Weinberg; pBabe puro HA PIK3CA was a gift from Jean Zhao (Addgene plasmid # 12522)³³; human Beta-Catenin pcDNA3 was a gift from Eric Fearon (Addgene plasmid # 16828)³⁴. The PIK3CA and β -Catenin constructs were engineered to express PIK3CA p.Gly106Val and β -Catenin p.Ser37Phe following QuickChange II XL Site-Directed Mutagenesis Kit protocol (Agilent Technologies). The p.Ser37Phe encoding *CTNNB1* fragment was then sub-cloned in a pQCXIB retroviral construct for stable overexpression, using sticky ends ligation with ApaI and BamHI-HF (New England BioLabs) restriction enzymes, per manufacturer's instructions. HEK293-FT cells were transfected with pBABE (empty vector), pBABE-*PIK3CA* encoding p.Gly106Val, pQCXIB (empty vector) and pQCXIB-*CTNNB1* encoding p.Ser37Phe using Fugene 6 (Promega) per manufacturer's instructions. Virus containing media was harvested at 24 hrs and 48 hrs post-transfection. HCC827 cells were infected with virus containing media, supplemented with 8 μ g/ml of polybrene (Sigma-Aldrich), for 24 hours. The culture medium was changed to standard growth media for an over-night incubation, after which cells were incubated in antibiotic selecting medium containing puromycin 1 μ g/mL (Gibco) for p-Babe construct or blasticidin 2.5 μ g/mL (Gibco) for pQCXIB constructs. Antibiotic resistant cells were used in the subsequent tests.

Cell Viability and Growth Assays—One hundred thousand of HCC827 cells, engineered with the β -Catenin p.Ser37Phe and PIK3CA p.Gly106Val expression constructs, and under puromycin (1 μ g/mL) and blasticidin (2.5 μ g/mL) selection, were seeded in 12 well plates and, after 24 hrs, treated with DMSO (control), erlotinib (50–100 nM) and rociletinib (100 nM), in 2% FBS, for three days. Cells were then air-dried for 5 minutes, fixed for 5 minutes in ParaFormaldehyde (PFA, 4% vol/vol; Santa Cruz Biothechnology) and stained in 0.05% crystal violet (g/mL; Sigma-Aldrich) solution for 30 minutes. Each well was washed twice with tap water and air-dried. Plates were scanned using ImageQuant LAS4000 (GE Healthcare Life Sciences). Each image is representative of a triplicate experiment. Cell viability was assessed using the above culture conditions, seeding two hundred of cells each well. Cell count was registered after three days of growth and assessed using Vi-CELL XR. Each test was run in triplicate.

Invasion and Migration Assays—Transwell migration and invasion assays were performed as described in Okimoto *et al.*³⁵ Briefly, 8- μ m-pore Matrigel coated (invasion) or non-coated (migration) Transwell inserts (BD Biosciences) were added at the top of a Transwell chamber filled with 10% FBS, RPMI media. To each insert, 2.4×10^4 cells in serum-free media were added. The Transwell chambers were incubated for 20 hrs at 37 °C in the incubator. Cells that did not migrate through the pore or invade the matrigel were scraped off; the membranes were fixed in methanol for 15 min and then stained with crystal violet for 30 min. The surface of the membrane was imaged in 5 distinct fields, with a Zeiss Axioplan II immunofluorescent microscope at 10 \times . Invasion and migration were assessed counting the average imaged cells in the 5 regions. Results presented are from three independent experiments.

Immunoblotting and q-RT-PCR—The HCC827 cells engineered with the β -Catenin p.Ser37Phe and PIK3CA p.Gly106Val expression constructs were drug treated, in serum free condition, with DMSO (control), erlotinib (100 nM) and rociletinib (100 nM) for 24 hrs. Protein lysates were collected in RIPA buffer supplemented with protease (Roche) and phosphatase (Roche) inhibitors. Western blot was performed loading 10 μ g of lysed proteins. Pre-casted 4–15% gels (Bio-Rad) were used for the mono-dimension protein separation. Proteins were transferred on nitrocellulose membranes using Trans-blot Turbo Transfer system (Bio-Rad). Blots were then blocked in Tris-buffered saline, 0.1% Tween20 (vol/vol) and 5% BSA (Fischer Scientific, vol/vol) for 1 hr, at room temperature. The primary antibodies were incubated over-night, at 4°C. The primary antibodies used were: pY1068-EGFR D7A5 (#3777), total EGFR D38B1 (#4267), β -Catenin D10A8 (#8480), pS473-AKT D9E (#4060), total AKT (#9272), pT202/Y204-ERK1/2 (#9101), total ERK1/2 (#9102) and cleaved PARP (#9541) from Cell Signaling Technology; Actin AC-74 (#A2228) from Sigma-Aldrich. The membranes were washed twice in washing buffer (Tris-buffered saline, 0.1% Tween20, vol/vol) and then incubated with secondary HRP conjugated antibodies for 1 hr, at room temperature. ECL kit (GE Healthcare) was used as chemoluminescent substrate. Blots were developed and scanned using ImageQuant LAS4000 (GE Healthcare Life Sciences). ImageJ (NIH) was used to quantify the western blots. All western blots represent the result of three independent experiments.

The RNA was purified from the HCC827 cells engineered with the β -Catenin p.Ser37Phe and PIK3CA p.Gly106Val expression constructs using RNeasy Micro Kit (Qiagen). One microgram of total RNA was used for the reverse-transcriptase reaction with SensiFAST cDNA Synthesis Kit (BIOLINE). The q-PCR was performed with six replicates each condition and using a 1:3 dilution of the template cDNA. Human *MYC*, *CCND1*, *LEF1*, *HOXB9*, and endogenous control *GAPDH* genes were amplified with Taqman gene expression assay (Applied Biosystems). Gene expression analysis was computed using QuantStudio 12K Flex Software (Applied Biosystems). Data were analyzed using the $2^{-\Delta\Delta C_t}$ method and expressed as relative mRNA expression.

Immunohistochemistry—Immunohistochemistry was performed as described³⁶. Briefly, 5-micron thick formalin-fixed paraffin embedded (FFPE) human tissue sections were stained with the β -Catenin D10A8 (#8480 Cell Signaling, 1:100 dilution), or pSer473-Akt D9E (#4060, Cell Signaling, 1:100 dilution) antibody per manufacturer's instructions. Stained slides were digitized using the Aperio ScanScope CS Slide Scanner (Aperio Technologies) with a 20 \times objective. The proportion of cells exhibiting nuclear β -Catenin staining was determined using the ScanScope default nuclear algorithm. pSer473-Akt quantitation was determined using the ScanScope default membrane algorithm. Three fields of view per section were used to determine the mean and standard error of the mean of positively staining cells.

Statistics—To determine differences in cfDNA alterations between cohorts two-tailed Fischer's Exact test with Benjamini-Hochberg method to correct for multiple hypothesis testing and generate q-values was used (Figs. 1c,e, 2c,f, 3c,d, 4e, Supplementary Figs. 3 and 9). We considered the false discovery rate to be controlled under 20% ($q < 0.2$).³⁷ For supplementary tables 3 and 4, two-tail t-test was used for two population mean difference with 95% confidence interval. The effect size, Cohen's d was determined by the equation: $(\text{Mean1} - \text{Mean2}) / \text{SD}_{\text{pooled}}$, where $\text{SD}_{\text{pooled}} = (\text{SD1} + \text{SD2}) / 2$; proportions test was used for two population proportion comparison with 95% confidence interval, no correction was used. In some conditions, 95% confidence interval for the single population proportion was used. The odds ratio (OR) was calculated for the measure of effect size between two population with proportion comparison. For PFS (Fig. 4 and Supplementary Fig. 3) and OS (Supplementary Fig. 4) assessments, the 95% CI for median duration of progression free survival and overall survival were computed using robust nonparametric Brookmeyer and Crowley method. Hazard ratio with 95% CI and *P*-values were calculated with Cox proportional hazards regression model with survival package in R. For Q-PCR, cell growth, invasion, and migration analysis (Fig. 6) one-way ANOVA and with Bonferroni correction were used to determine *P*-values (GraphPad Prism).

Data Availability

The data supporting the findings of the study are available within the paper and its supplementary information files and have been deposited publically in the European Genome-phenome Archive (EGA), accession number: *EGAS00001002604*.

Code availability

Most bioinformatics tools used in the analysis of this dataset are publicly available; any that are not are available on request.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors acknowledge funding support from NIH: NCI-R01CA169338, NIH Director's New Innovator Award NCI-DP2CA174497, the Pew Charitable Trust, Stewart Foundation, and Searle Foundation (to T.G.B), and to AACR and Lung Cancer Research Foundation (C.M.B.). The authors thank J. Blakely for artwork and A. Sabnis, R. Okimoto, A. Tulpule, and M. Hutchinson for critical review and input on the manuscript.

References

1. de Bruin EC, et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. *Science*. 2014; 346:251–6. [PubMed: 25301630]
2. Zhang J, et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. *Science*. 2014; 346:256–9. [PubMed: 25301631]
3. Turke AB, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. *Cancer Cell*. 2010; 17:77–88. [PubMed: 20129249]
4. Zhang Z, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. *Nat Genet*. 2012; 44:852–60. [PubMed: 22751098]
5. Chabon JJ, et al. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. *Nat Commun*. 2016; 7:11815. [PubMed: 27283993]
6. VanderLaan PA, et al. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes. *Lung Cancer*. 2017; 106:17–21. [PubMed: 28285689]
7. Canale M, et al. Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors. *Clin Cancer Res*. 2017; 23:2195–2202. [PubMed: 27780855]
8. Comprehensive molecular profiling of lung adenocarcinoma. *Nature*. 2014; 511:543–50. [PubMed: 25079552]
9. Lanman RB, et al. Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA. *PLoS One*. 2015; 10:e0140712. [PubMed: 26474073]
10. Thompson JC, et al. Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA. *Clin Cancer Res*. 2016; 22:5772–5782. [PubMed: 27601595]
11. Yu H, et al. Analysis of Mechanisms of Acquired Resistance to EGFR TKI therapy in 155 patients with EGFR-mutant Lung Cancers. *Clin Cancer Res*. 2013; 19:2240–2247. [PubMed: 23470965]
12. Yu HA, et al. Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing. *Ann Oncol*. 2014; 25:423–8. [PubMed: 24478319]
13. Politi K, Fan PD, Shen R, Zakowski M, Varmus H. Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma. *Dis Model Mech*. 2010; 3:111–9. [PubMed: 20007486]
14. Eberlein CA, et al. Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models. *Cancer Res*. 2015; 75:2489–500. [PubMed: 25870145]
15. Thress KS, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. *Nat Med*. 2015; 21:560–2. [PubMed: 25939061]

16. Ou SH, Agarwal N, Ali SM. High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression. *Lung Cancer*. 2016; 98:59–61. [PubMed: 27393507]
17. Ho CC, et al. Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib. *J Thorac Oncol*. 2016
18. Sequist LV, et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. *N Engl J Med*. 2015; 372:1700–9. [PubMed: 25923550]
19. Gamallo C, et al. beta-catenin expression pattern in stage I and II ovarian carcinomas : relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome. *Am J Pathol*. 1999; 155:527–36. [PubMed: 10433945]
20. Wang XY, Repasky E, Liu HT. Antisense inhibition of protein kinase Calpha reverses the transformed phenotype in human lung carcinoma cells. *Exp Cell Res*. 1999; 250:253–63. [PubMed: 10388539]
21. Burke JE, Perisic O, Masson GR, Vadas O, Williams RL. Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110alpha (PIK3CA). *Proc Natl Acad Sci U S A*. 2012; 109:15259–64. [PubMed: 22949682]
22. Trejo CL, et al. Mutationally activated PIK3CA(H1047R) cooperates with BRAF(V600E) to promote lung cancer progression. *Cancer Res*. 2013; 73:6448–61. [PubMed: 24019382]
23. Dorantes-Heredia R, Ruiz-Morales JM, Cano-Garcia F. Histopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumors. *Transl Lung Cancer Res*. 2016; 5:401–12. [PubMed: 27652204]
24. Sequist LV, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. *Sci Transl Med*. 2011; 3:75ra26.
25. Piotrowska Z, et al. Heterogeneity Underlies the Emergence of EGFR T790M Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. *Cancer Discov*. 2015; 5:713–22. [PubMed: 25934077]
26. Ortmann CA, et al. Effect of mutation order on myeloproliferative neoplasms. *N Engl J Med*. 2015; 372:601–12. [PubMed: 25671252]
27. Villaflor V, et al. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer. *Oncotarget*. 2016; 7:66880–66891. [PubMed: 27602770]
28. Newman AM, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. *Nat Med*. 2014; 20:548–54. [PubMed: 24705333]
29. Jamal-Hanjani M, et al. Tracking the Evolution of Non-Small-Cell Lung Cancer. *N Engl J Med*. 2017; 376:2109–2121. [PubMed: 28445112]
30. Campeau E, et al. A versatile viral system for expression and depletion of proteins in mammalian cells. *PLoS One*. 2009; 4:e6529. [PubMed: 19657394]
31. Morgenstern JP, Land H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. *Nucleic Acids Res*. 1990; 18:3587–96. [PubMed: 2194165]
32. Stewart SA, et al. Lentivirus-delivered stable gene silencing by RNAi in primary cells. *RNA*. 2003; 9:493–501. [PubMed: 12649500]
33. Zhao JJ, et al. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. *Proc Natl Acad Sci U S A*. 2005; 102:18443–8. [PubMed: 16339315]
34. Kolligs FT, Hu G, Dang CV, Fearon ER. Neoplastic transformation of RK3E by mutant beta-catenin requires deregulation of Tcf/Lef transcription but not activation of c-myc expression. *Mol Cell Biol*. 1999; 19:5696–706. [PubMed: 10409758]
35. Okimoto RA, et al. Inactivation of Capicua drives cancer metastasis. *Nat Genet*. 2017; 49:87–96. [PubMed: 27869830]
36. Blakely CM, et al. NF-kappaB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer. *Cell Rep*. 2015; 11:98–110. [PubMed: 25843712]

37. Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A*. 2005; 102:15545–50. [PubMed: 16199517]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 1. Co-occurring genomic alterations detectable in cell-free DNA of advanced-stage *EGFR*-mutant positive compared to *EGFR*-mutant negative non-small cell lung cancer (NSCLC) patients

(a) Frequency of genomic alterations: non-synonymous somatic variants of predicted functional significance (SNV, see Methods), copy number gains (CNG), insertions or deletions (INDEL), or gene rearrangements (FUSION) in the cancer-related genes listed (Supplementary Table 2), detected by next-generation sequencing of circulating tumor DNA from 1122 advanced-stage *EGFR*-mutant positive NSCLC patients (a) compared to a cohort of 944 *EGFR*-mutant negative NSCLC patients (b) (Supplementary Datasets 1 and 2). Co-

occurring alterations that occurred in at least 5% of *EGFR*-mutant positive cases are shown. * Indicates statistically significant differences between the cohorts ($q < 0.2$). **(c)** Gene alterations with increased frequency in *EGFR*-mutant positive compared to *EGFR*-mutant negative patients (Two-tailed Fisher's exact test performed to identify statistically significant differences in *TP53*, *CDK6*, *CTNNB1*, and *AR*, using Benjamini-Hochbeg correction for multiple hypothesis testing (q -values). **(d)** Lollipop plots of gene level alterations in *EGFR*-mutant positive compared to *EGFR*-mutant negative samples. The functional significance of somatic variants is indicated based on analysis described in Methods. **(e)** Differences in pathway level alterations between *EGFR*-mutant positive and *EGFR*-mutant negative cases (two-tailed Fisher's Exact test comparing *EGFR*-mutant positive to *EGFR* mutant-negative with Benjamini-Hochbeg correction for multiple hypothesis testing (q -values). See also Supplementary Tables 1–3 and Supplementary Datasets 1 and 2.




Figure 2. Co-occurring genomic alterations detected in cell-free DNA of 440 advanced-stage *EGFR*-mutant, p.Thr790Met positive compared to 682 advanced-stage *EGFR*-mutant, p.Thr790Met negative NSCLC patients

(a–b) Frequency of non-synonymous genomic alterations of known or predicted functional significance: somatic variants (SNV), copy number gain (CNG), insertions or deletions (INDEL), or gene rearrangements (FUSION) in cancer-related genes detectable by next-generation sequencing (in at least 5% of p.Thr790Met positive cases) of circulating tumor DNA are indicated in (a) *EGFR*-mutant, p.Thr790Met (denoted as T790M) positive (n=440) and (b) *EGFR*-mutant, p.Thr790Met negative (n=682) cohorts. *Q*-values determined by two-

tailed by Fisher's Exact test with Benjamini-Hochberg correction for multiple hypothesis testing * Indicates statistically significant differences between the cohorts ($q < 0.2$). (c) Frequency (percentage) of gene level alterations detectable in the cell-free DNA of *EGFR*-mutant, p.Thr790Met positive compared *EGFR*-mutant, p.Thr790Met negative patients (q -values determined by two-tailed by Fisher's Exact test with Benjamini-Hochberg correction for multiple hypothesis testing). (d–e) Lolliplots of gene level alterations in *EGFR*-mutant, p.Thr790Met positive compared to *EGFR*-mutant, p.Thr790Met negative samples. Somatic alterations in *CTNNB1* (d) and *KRAS* (e) are indicated. The functional significance of somatic variants is indicated based on analysis described in Methods. (f) Differences in pathway level alterations between *EGFR*-mutant p.Thr790Met positive and *EGFR*-mutant p.Thr790Met negative cases determined by two-tailed Fisher's Exact test with Benjamini-Hochberg correction for multiple hypothesis testing (q -value). See also Supplementary Figure 1, Supplementary Table 4 and Supplementary Dataset 1.




Figure 3. Therapy-induced evolution of genomic co-alterations detected in cell-free DNA of advanced-stage EGFR-mutant NSCLC patients
 cfDNA analysis of 137 samples collected from 97 patients with known clinical history (see also Supplementary Table 5 and Supplementary Dataset 3). (a) Samples were segregated by EGFR TKI treatment; pre-TKI (n=21), at the time of progression to first-line EGFR TKI therapy; PD to 1st line (n=53), or at the time of progression to 2nd line anti-cancer therapy (2nd or 3rd generation EGFR TKI, or chemotherapy); PD to 2nd line (n=26). (b) Number of functional alterations detectable based on line of therapy are indicated (mean ± 95% CI).

Pre-TKI (3.4, 95% CI: 2.2–4.5), PD to 1st line (3.8, 95% CI: 3.2–4.4), PD to 2nd line (5.2, 95% CI: 4.1–6.3). Pre-TKI vs. PD to 1st line $P=0.8$, Pre-TKI vs. PD to 2nd line $P=0.03$, PD to 1st line vs. PD to 2nd line $P=0.04$, $F=4.3$, $DF=97$, ANOVA with Tukey correction for multiple comparisons. **(c)** Changes in gene alteration frequency (percentage) with line of therapy **(d)** Changes in cancer-related pathway alterations (percentage) with line of therapy. **(c and d)** Two-way Fisher's exact test was performed to identify statistically significant differences between pre-TKI and PD to 1st line, between PD to 1st line and PD to 2nd line, and between pre-TKI and PD to 2nd line with Benjamini-Hochberg correction for multiple hypothesis testing (q -values). See also Supplementary Figures 2–5, Supplementary Tables 5, and Supplementary Dataset 3.




Figure 4. Effect of cfDNA detectable co-occurring genetic alterations on osimertinib clinical response in advanced-stage *EGFR*-mutant lung cancer patients

(a–b) Genomic alterations detectable in cfDNA from advanced *EGFR*-mutant NSCLC patients who were subsequently treated with osimertinib and exhibited a radiographic/clinical response (a) (PR by clinician assessment, see methods) versus patients who did not respond (b) (by clinician assessment, see methods). (c) Forrest plot demonstrating effect of cfDNA detectable gene level alterations on PFS with *P*-values determined by Cox-proportional Hazard Ratio (HR) with 95% CI. (d) Kaplan-Meier curves demonstrating

difference in median PFS (logrank test) in patients with cfDNA detectable alterations in *CDK4* or *CDK6*. **(e)** Pathway level alterations in osimertinib responders vs. non-responders. *Q*-values determined by two-tailed Fisher's Exact test with Benjamini-Hochberg correction for multiple hypothesis testing. **(f–g)** Forrest plot and Kaplan-Meier curves assessing the effects of indicated cfDNA detectable pathway alterations on PFS with *P*-values determined by Cox-proportional Hazard Ratio (HR) with 95% CI. See also Supplementary Figures 4 and 5, Supplementary Table 6 and Supplementary Dataset 4.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 5. Longitudinal genomic analysis of tumor and cell-free DNA in a patient with *EGFR*-mutant lung cancer from diagnosis to death
(a) Heatmap depicting the clonal status of non-synonymous somatic mutations including SNVs, dinucleotides and indels from each sequenced region of the patient’s disease as determined by subclonal copy number corrected cancer cell fraction and PyClone cross sample clustering. Somatic alterations were detected by whole-exome sequencing of the tumor DNA of the patient at initial presentation and surgical resection of *EGFR*-mutant lung cancer (R1), at the time of development of metastatic disease (R2), upon progression to first

line treatment with erlotinib (R3), and at autopsy after treatment with the 2nd line EGFR TKI rociletinib followed by PD and death (R4-R7). (see Methods for description of analysis). **(b)** Phylogenetic tree illustrating the evolutionary history of the patient's disease at the level of subclonal clusters of mutations. These subclonal clusters are inferred, using PyClone, from the samples taken from the primary and different metastases at multiple time-points. The mutations were clustered based on their prevalence (subclonal copy number corrected cancer cell fraction) in the sequenced cancer cell populations across all samples, this clustering is then used to infer the founding clone (at the bottom of the tree) and subclonal clusters. **(c)** Pictorial representation of primary tumor and metastatic sites analyzed by whole exome sequencing. **(d)** cfDNA detectable in plasma from patient at indicated time points as determined by CAPP-Seq analysis⁵. See also Supplementary Figs. 6–8, and Supplementary Datasets 5 and 6.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 6. Functional analysis of *CTNNB1* and *PIK3CA* co-mutations detected in *EGFR*-mutant lung adenocarcinoma

(a) IHC staining for nuclear β -Catenin or serine-473-phosphorylated AKT (Mean \pm S.E.M. images representative of 3 images per panel, scale bar = 50 microns). (b) Immunoblot analysis of HCC827 cells infected with empty vector (E.V.) or constructs that overexpress β -Catenin p.Ser37Phe, PIK3CA p.Gly106Val, or both proteins. Cells were treated with 100 nM erlotinib (E) or rociletinib (R) or vehicle control (veh), and immunoblot analysis performed on cellular extracts. Relative proportions of cleaved-PARP to total PARP and p-

AKT to total AKT are indicated. Images are representative of immunoblots from 3 independent cell culture experiments (c) Cellular viability assay (Methods) of HCC827 NSCLC cells engineered to overexpress β -Catenin p.Ser37Phe and/or PIK3CA p.Gly106Val. Relative cell viability compared to DMSO-treated control is indicated. Images are representative of 3 independent cell culture experiments. Cellular growth (d), invasion (e) and migration (f) assays (Methods) comparing HCC827 cells engineered to express the indicated proteins (mean \pm S.E.M. from 3 independent cell culture experiments, *P*-Values determined by ANOVA with Bonferroni's correction). (d) $F=4.844$, $DF=8$. (e), $F=5.095$, $DF=8$. (f), $F=9.633$, $DF=8$. (g) Quantitative-PCR (Q-PCR) of β -Catenin target genes (mean \pm S.E.M from 2 independent experiments). *P*-Values compared to PIK3CA p.Gly106Val control, ANOVA with Bonferroni's correction (*MYC*: $F=6.5$, $DF=3$; *CCND1*: $F=107$, $DF=3$; *LEF1*: $F=9.5$, $DF=3$; *HOXB9*: $F=23.3$, $DF=3$).




Figure 7. Clonality analysis of co-occurring genetic alterations detectable in the cfDNA of advanced-stage NSCLC patients

The distribution of clonal and subclonal alterations were determined in (a) *EGFR*-mutant positive (n=1122) vs. *EGFR*-mutant negative (n=944) NSCLC, and (b) *EGFR*-mutant p.Thr790Met (T790M) positive (n=440) vs. *EGFR*-mutant p.Thr790Met (T790M) mutant negative (n=682) NSCLC. Red line indicates division between clonal (≥ 0.2 MAF/Maximum MAF) and subclonal (< 0.2 MAF/Maximum MAF) as defined in the text and Supplementary

Fig. 10. *P*-values determined by two-tailed Fisher's Exact test. See also Supplementary Fig. 10 and Supplementary Datasets 1 and 2.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 8. Evolution of the understanding of the genetic pathogenesis of oncogene-positive (here, *EGFR*-mutant) lung cancer

(a) Traditional view of lung cancer based on histopathological analysis. Lung adenocarcinoma, scale bar = 50 microns. (b) Current molecular classification of NSCLC based on single-gene driver oncogene status, depicting the current view of mutually-exclusive driver oncogenes, as shown in the pie chart with frequency of each driver alteration in lung adenocarcinoma. (c) The proposed new model of *EGFR*-mutant NSCLC pathogenesis arising from our findings: a re-classification of advanced-stage *EGFR*-mutant NSCLC based on the co-occurring genetic alterations that our dataset revealed (shown here at the pathway level). We propose that advanced-stage *EGFR*-mutant NSCLCs contain co-occurring genetic alterations that function collaboratively as co-drivers of tumor progression and drug resistance. We now need to identify and co-target these co-occurring functional genetic alterations beyond mutant *EGFR* itself in patients, early and dynamically during treatment, in order to improve patient survival. The finding of extensive co-occurring alterations within advanced-stage *EGFR*-mutant NSCLC at scale now paves the way for studying the biological and clinical impacts of genetic interactions that are created by the co-alterations present in these *EGFR*-mutant NSCLCs.